Skip to nav Skip to content

COVID-19: Vaccine Information, General Information

Learn more about Seattle Children’s Anti-Racism Organizational Change plan and the independent review of efforts to combat systemic racism conducted by the Assessment Committee.

The Promise of Immunotherapy

Immunotherapy Trials

Immunotherapy holds much promise with its ability to target tumor cells specifically. Building on that promise, doctors and researchers at Seattle Children’s have begun a series of phase 1 trials called BrainChild. These trials test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG.

Read more about how CAR T-cell therapy works.

BrainChild Studies: Phase 1 Trials

BrainChild-01, -02 and -03 are Seattle Children’s phase 1 clinical trials using CAR T-cell therapy for brain and CNS tumors in children and young adults.

Seattle Children’s runs simultaneous clinical trials. This means that rather than waiting for the results of one trial before starting the next one, we share and apply knowledge that we gain from the trials while they are still ongoing. This process significantly speeds up the time spent researching new treatments and cures.

For more information about BrainChild studies, call 206-987-2106 or send us an email.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies